Balchem Corp (BCPC) · Oct 23, 2026 · Earnings
In line — Adjusted EPS $1.57 vs ~$1.57 consensus; sales $290.7M vs ~$289–295M
Balchem’s Q3 earnings were broadly in line with expectations, with sales growth across all three segments, wider margins, and stronger cash flow.
Balchem is a specialty-ingredients company building around human nutrition, animal nutrition, and specialty products such as performance gases and plant nutrients. Its current growth story is led by differentiated nutrition technologies and a broad innovation pipeline across those markets.
The quarter was essentially on the market’s numbers, not a surprise beat. Published estimates clustered around roughly $289–295 million of revenue and $1.57 of adjusted EPS; Balchem delivered $290.7 million and $1.57, respectively.
| Metric | Q3 2026 | Q3 2025 | Change / comparison |
|---|---|---|---|
| Net sales | $290.7M | $267.6M | +8.6% |
| GAAP diluted EPS | $1.46 | $1.24 | +17.7% |
| Adjusted diluted EPS | $1.57 | $1.35 | +16.3%; in line with consensus |
| Adjusted EBITDA | $80.3M | $71.4M | +12.4% |
| Free cash flow | $57.9M | $50.7M | +14.3% |
| Gross margin | 36.4% | 35.7% | +70 bps |
The underlying business remained broad-based rather than dependent on one segment. Human Nutrition and Health, the largest division, grew sales 8.1% and operating earnings 11.8%, while Animal Nutrition and Health grew sales 11.7% and operating earnings 82.8%. Specialty Products also grew sales 4.5% and operating earnings 6.6%.
Profit conversion was better than the sales growth. Gross margin expanded 70 basis points to 36.4%, helped by favorable mix and manufacturing efficiencies, while adjusted EBITDA rose 12.4%—ahead of the 8.6% sales increase. That makes this more than a volume-only quarter, although the company still cited higher manufacturing input costs as a partial offset.
Cash generation and balance-sheet execution continued to support the growth plan. Nine-month operating cash flow reached $156.5 million, free cash flow was $128.0 million, and revolving debt fell to $124.0 million from $164.0 million at year-end. The company also repurchased about $28 million of stock during the quarter.
There was no new full-year guidance or strategic reset in this filing. Management reiterated confidence in the long-term growth outlook and highlighted upcoming product innovation, so the release strengthens the existing execution story rather than materially changing it.
Bottom line: This was a solid, broad-based quarter that met expectations rather than exceeded them. The business is executing cleanly—with improving margins, cash flow, and leverage—but the filing adds confirmation more than surprise.
SupplySide Global product showcase
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!